Author(s):
Md. Nazmul Sardar, Ekhlass Uddin, Md. Shahin Reza, Shajahan Talukdar Sunny, Md. Faysal Khan Shuvo, Md. Mamun Hossain, Md. Faruk Hossen, Md. Ali Asraf, Md. Kudrat-E-Zahan
Email(s):
kudrat.chem@ru.ac.bd , nazmulsardar91@gmail.com , ekhlassuddin@gmail.com
DOI:
10.52711/0974-4150.2024.00058 
Address:
Md. Nazmul Sardar1, Ekhlass Uddin2, Md. Shahin Reza3, Shajahan Talukdar Sunny4, Md. Faysal Khan Shuvo4, Md. Mamun Hossain5, Md. Faruk Hossen2, Md. Ali Asraf2,Md. Kudrat-E-Zahan6*
1Department of Pharmacy, University of Rajshahi, Bangladesh.
2Department of Chemistry, University of Rajshahi, Bangladesh.
3Department of Chemistry, Tennessee State University, Nashville, United States.
4Department of Pharmacy, Southeast University, Bangladesh.
5Department of Pharmacy, Rajshahi University, Rajshahi-6205, Bangladesh.
6Professor, Department of Chemistry, Rajshahi University, Bangladesh.
*Corresponding Author
Published In:
Volume - 17,
Issue - 6,
Year - 2024
ABSTRACT:
The investigation developed a new stability-indicating Reverse phase high-pressure liquid chromatographic (RP-HPLC) assay method to quantify Voglibose in bulk and pharmaceutical dosage form. The technique used isocratic elution on an Amino (NH2) column (250x4.6mm, 5µ particle size) with a mobile phase of Phosphate Buffer (pH 6.7) and Acetonitrile (27:73 v/v). The separation was monitored using UV detection at 210 nm. The method was validated, meeting ICH guidelines. The retention time of Voglibose was 6.38 minutes, and the linearity was between 24-56 µg/ml. The limit of detection and quantitation were 0.70 and 2.11 µg/ml, respectively. Analytical performance parameters were determined according to ICH guidelines. The method was simple, precise, accurate, robust, and rapid, making it suitable for quantifying Voglibose in bulk and tablet formulation.
Cite this article:
Md. Nazmul Sardar, Ekhlass Uddin, Md. Shahin Reza, Shajahan Talukdar Sunny, Md. Faysal Khan Shuvo, Md. Mamun Hossain, Md. Faruk Hossen, Md. Ali Asraf,Md. Kudrat-E-Zahan. A Novel Stability Indicating Analytical Development and Validation of an RP-HPLC Assay Method for the Quantification of Voglibose in Bulk and its Formulation. Asian Journal of Research in Chemistry.2024; 17(6):344-0. doi: 10.52711/0974-4150.2024.00058
Cite(Electronic):
Md. Nazmul Sardar, Ekhlass Uddin, Md. Shahin Reza, Shajahan Talukdar Sunny, Md. Faysal Khan Shuvo, Md. Mamun Hossain, Md. Faruk Hossen, Md. Ali Asraf,Md. Kudrat-E-Zahan. A Novel Stability Indicating Analytical Development and Validation of an RP-HPLC Assay Method for the Quantification of Voglibose in Bulk and its Formulation. Asian Journal of Research in Chemistry.2024; 17(6):344-0. doi: 10.52711/0974-4150.2024.00058 Available on: https://ajrconline.org/AbstractView.aspx?PID=2024-17-6-6
REFERENCES:
1. Nikita RB, and Mohit JS. Voglibose: An alpha glucosidase inhibitor. Journal of Clinical and Diagnostic Research. 2013; 7: 3023-3027, DOI: 10.7860/JCDR/2013/6373.3838
2. Chen X, Zheng Y, Shen Y. Voglibose, one of the most important alpha-glucosidase inhibitors. Current Medicinal Chemistry. 2006; 13: 109-116, DOI: 10.2174/092986706789803035
3. Selvaraj G, Kaliyamurthi S and Thirugnanasambandam R. Alpha-glucosidase inhibitory effect and enzyme kinetics of coastal medicinal plants. Bangladesh J Pharmacol. 2012; 7: 186-191, DOI:10.3329/bjp.v7i3.11499
4. Hiyoshi T, Shiozaki M, Inoue M, Takahashi T, Nishikawa F, Naito H. Clinical study of a fixed-dosed mitiglinide/voglibose combination in patients with Type 2 diabetes mellitus - Clinical assessment of glycemic markers, HbA1c, glycated albumin and 1,5-anhydroglucitol. Therapeutic Research. 2013, 34, 379-390
5. Nepal MR, Kang MJ, Kim GH, Cha DH, Kim JH, Jeong TC. Role of intestinal microbiota in metabolism of Voglibose In Vitro and In Vivo. Diabetes Metab J. 2020; 44: 908-918. DOI: 10.4093/dmj.2019.0147
6. Sivaram P. Potential drug combinations to reduce cardiovascular disease burden in diabetes. Trends in Pharmacological Sciences. 2016; 37: 207-219, DOI: https://doi.org/10.1016/j.tips.2015.11.009
7. Ahmad KDAK, Lim JY, Chin TL, Gan TF, Vasudeva RA. Rhodanine scaffold: A review of antidiabetic potential and structure-activity relationships (SAR). Medicine in Drug Discovery. 2022; 15, DOI: https://doi.org/10.1016/ j.medidd.2022.100131
8. Thundiparambil AS, Chandra PS. 1-Diabetes mellitus–an overview. In Woodhead Publishing Series in Biomedicine. 2014; 1-57, DOI: https://doi.org/10.1533/9781908818683.1
9. Derosa G, Maffioli P. α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci. 2012; 8: 899-906, DOI: 10.5114/ aoms.2012.31621
10. Karunanidhi L, Tirumala R. Determination of voglibose in pharmaceutical formulations by high performance liquid chromatography using refractive index detection. European Journal of Chemistry. 2010; 1: DOI: 10.5155/eurjchem.1.4.262-265.116
11. Kishore VS, Jitendrakumar P, Chakravarthy TK, Naik SV, Reddy MH and Babu EN. Development and validation of RP-HPLC method for quantitative analysis voglibose in pure and pharmaceutical formulations. International Journal of Pharmaceutical, Chemical And Biological Sciences. 2013; 3: 336-341
12. Daswadkar SC, Walode SG and Mahendra KCB. Stability indicating RP-HPLC method for estimation of voglibose in bulk and tablet dosage form. Pharmacophore. 2013; 4: 158-165
13. Nowrouzi-Sohrabi P, Tabrizi R, Rezaei S, Jafari F, Hessami K, Abedi M, Jalali M, Keshavarzi P, Shahabi S, Kolahi AA, Carson-Chahhoud K, Sahebkar A, Safiri S. The effect of voglibose on metabolic profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials. Pharmacol Res. 2020; DOI: 10.1016/j.phrs.2020.104988
14. Rao NM, Janardhanan B, Ravi TK, Kumar DK, Mogili R. RP-HPLC method development and validation for estimation of Voglibose in bulk and tablet dosage forms. International Journal of Research in Pharmaceutical Sciences. 2010
15. Patel SA, Patel NJ. Development and validation of HPLC method for estimation of voglibose in bulk and tablets. J Pharm Educ Res. 2011; 2: 78-83
16. Chew YL, Khor MA, Lim YY. Choices of chromatographic methods as stability indicating assays for pharmaceutical products: A review. Heliyon. 2021; 27: DOI: 10.1016/ j.heliyon.2021.e06553
17. Parmar N, Gupta AK, Jhaveri K, A B, Chhaya G, Kansara S, Nair R, Korukonda KR. Real-World assessment of personalized approach with voglibose fixed-dose combination in type 2 diabetes mellitus. Cureus. 2024; 16: DOI: 10.7759/cureus.57494